MS-N136 · Supportive care · Human evidence · Appraised 25 October 2026

Do vaginal dilators prevent vaginal narrowing after pelvic radiotherapy?

Evidence at a glance

• Evidence label: Commonly recommended, but direct evidence is limited and timing matters
• Benefit: One underpowered randomized trial found less worsening on a clinician stenosis scale, but no preservation of measured vaginal volume.
• Certainty: Low because the dilator group was small, adherence was imperfect, the trial was open-label and a Cochrane review found no reliable high-quality proof.
• Risk: Pain, bleeding, mucosal injury and rare serious trauma are possible if dilation begins during acute inflammation or is forced.

What was studied

Population and design: An open-label Brazilian trial randomized 195 women with stage I–IIIB cervical cancer after radiotherapy to topical estrogen (66), testosterone (34), water-based lubricant (66) or vaginal dilators (29). Only 142 completed 12-month assessment.

Studied regimen: Dilator use began after radiotherapy and was instructed daily. Product size, frequency and start date should be individualized; this trial does not support using a dilator during acute radiation injury.

What the evidence found

Across all four groups, mean estimated vaginal volume fell about 25%, with no significant between-group difference. CTCAE stenosis worsened over one year in the hormone and lubricant groups but not in the dilator group (within-group P=.37); the small dilator arm and lack of a direct powered between-group benefit make that signal uncertain.

A Cochrane review found no reliable randomized evidence that routine dilation during or immediately after radiotherapy prevents late stenosis and noted rare injuries. Observational associations are difficult to interpret because people able to use a dilator may already have less pain or tissue injury.

How to interpret it

Dilation may help maintain examination access, flexibility or sexual comfort for some survivors, but it is not a proven one-size-fits-all preventive schedule. The outcome is tissue function after radiotherapy, not tumor response. Shared planning matters because adherence and distress are important clinical outcomes.

Practical safety context

Wait until the radiation or gynecologic team says tissue healing is adequate. Use lubrication and gentle progression; stop for significant pain, persistent bleeding, foul discharge or new pelvic symptoms. Unexplained bleeding requires examination rather than simply changing dilator size.

Questions for the care team

• When has acute mucositis healed enough to start safely?
• What size, frequency and duration are appropriate for the radiation field and symptoms?
• Is pelvic-floor therapy, sexual-health support or a smaller device more tolerable?

Funding and conflicts

The randomized trial was funded by the São Paulo Research Foundation and registered retrospectively (RBR-23w5fv). Its completed sample provided only 44.9% power for the stenosis-scale outcome and 10.8% for vaginal-volume change.

Sources

• Open-label randomized trial (PMID 34112100)
• DOI 10.1186/s12885-021-08274-w
• Cochrane review of vaginal dilation (PMID 25198150)

Last literature search: 25 October 2026. Record appraisal: 25 October 2026. This page is educational and does not replace individualized medical advice. Symptom or function improvement must not be interpreted as evidence of tumor response, delayed recurrence or longer survival.